相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
Vaishali Sanchorawala et al.
BLOOD (2007)
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2007)
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
Angela Dispenzieri et al.
BLOOD (2007)
Transplantation for amyloidosis
Morie A. Gertz et al.
CURRENT OPINION IN ONCOLOGY (2007)
Systemic immunoglobulin light-chain amyloidosis
Raymond L. Comenzo
CLINICAL LYMPHOMA & MYELOMA (2006)
Outcome of autologous stem cell transplantation for AL amyloidosis in the UK
Hugh J. B. Goodman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: A Center for International Blood and Marrow Transplant Research study
David H. Vesole et al.
MAYO CLINIC PROCEEDINGS (2006)
Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?
N. J. Bahlis et al.
BONE MARROW TRANSPLANTATION (2006)
Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis
JB Perz et al.
BONE MARROW TRANSPLANTATION (2006)
Prevalence and determinants of troponin T elevation in the general population
TW Wallace et al.
CIRCULATION (2006)
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
A Dispenzieri et al.
BLOOD (2006)
Early treatment-related mortality in adult autologous stem cell transplant recipients:: a nation-wide survey of 1482 transplanted patients
E Jantunen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2006)
Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients
N Leung et al.
BLOOD (2005)
Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience
LQM Chow et al.
BONE MARROW TRANSPLANTATION (2005)
Risk stratification in cardiac amyloidosis: Novel approaches
AV Kristen et al.
TRANSPLANTATION (2005)
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
G Palladini et al.
BLOOD (2005)
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
G Palladini et al.
BLOOD (2004)
Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome
PN Mollee et al.
BONE MARROW TRANSPLANTATION (2004)
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
M Skinner et al.
ANNALS OF INTERNAL MEDICINE (2004)
Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
DC Seldin et al.
BLOOD (2004)
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
A Dispenzieri et al.
BLOOD (2004)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
VAD with or without subsequent melphalan followed by autologous high-dose stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection
T Gono et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2004)
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate
MA Gertz et al.
BONE MARROW TRANSPLANTATION (2004)
Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628
MV Dhodapkar et al.
BLOOD (2004)
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study
A Dispenzieri et al.
BLOOD (2004)
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
A Dispenzieri et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2003)
Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins
A Dispenzieri et al.
LANCET (2003)
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis
G Palladini et al.
CIRCULATION (2003)
Stem cell transplantation for the management of primary systemic amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF MEDICINE (2002)
Autologous stem cell transplantation for primary systemic amyloidosis
RL Comenzo et al.
BLOOD (2002)
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
